Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

INTRODUCTION: Diroximel fumarate (DRF) is a novel oral fumarate in development for patients with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development program suggest that rates of gastrointestinal (GI) treatment-emergent adverse events (TEAEs) and discontinuation du...

Descripción completa

Detalles Bibliográficos
Autores principales: Palte, Michael J., Wehr, Angela, Tawa, Mark, Perkin, Kristopher, Leigh-Pemberton, Richard, Hanna, Jerome, Miller, Catherine, Penner, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822793/
https://www.ncbi.nlm.nih.gov/pubmed/31538304
http://dx.doi.org/10.1007/s12325-019-01085-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822793/
https://www.ncbi.nlm.nih.gov/pubmed/31538304
http://dx.doi.org/10.1007/s12325-019-01085-3

Ejemplares similares